Portrait of Jill N. Burke, CNP, DipACLM

Jill N. Burke,

CNP, DipACLM

Jill N. Burke,

CNP, DipACLM

Massachusetts General Hospital

Jill N. Burke,

CNP, DipACLM

Massachusetts General Hospital

Jill Burke, CNP, DipACLM, has spent the last 35 years at Massachusetts General Hospital; first, 12 years as inpatient heme-onc staff nurse, and the last 23 years at a nurse practitioner. Jill’s focus of care has been multiple myeloma for 15 years. She presently works in the outpatient setting, managing patients with plasma cell diseases throughout diagnosis and treatment.

She is a strong patient advocate, ensuring that patients reach their optimal level of functioning and enjoy life. She is known for explaining to newly diagnosed patients that she hopes their diagnosis will occupy a small sliver in the pie of their life. Jill is certified by the American College of Lifestyle Medicine as a lifestyle coach, and she is in the process of organizing lifestyle medicine clinics for patients diagnosed with monoclonal gammopathy of unknown significance (MGUS), multiple myeloma, and post CAR-T. Jill has given talks and presented posters both nationally and internationally.

Portrait of Jill N. Burke, CNP, DipACLM

Jill's Shared Resources

SHIVERING 2 Trial Shows Tandem High-Dose Influenza Vaccines Significantly Improve Protection in Plasma Cell Dyscrasia Patients

Plasma cell dyscrasias (PCDs), like multiple myeloma, are hematologic disorders that lead to compromised immune responses, making vaccinations, particularly against influenza, less effective in patients with PCDs due to their...
CURATED BY:
Jill N. Burke,
CNP, DipACLM

Study Highlights Increased COVID-19 Risks and Management Challenges for Multiple Myeloma Patients

Researchers assessed patients with multiple myeloma (MM) and their vulnerable to infections, including COVID-19, due to the disease and treatments compromising their immune system. This vulnerability is exacerbated by age,...
CURATED BY:
Jill N. Burke,
CNP, DipACLM

Study Highlights Age-Related Treatment Outcomes in Myeloma, Underscores Need for Personalized Approaches

A study assessed treatments for myeloma, noting advancements in patient outcomes due to proteasome inhibitors and immunomodulatory drugs, yet acknowledging persistently poor results in high-risk cases marked by rapid disease...
CURATED BY:
Jill N. Burke,
CNP, DipACLM

Provided by an unrestricted grant from

Provided by an unrestricted grant from

Share